Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group [see comments]
Menache, D, O'Malley, JP, Schorr, JB, Wagner, B, Williams, C, Alving, BM, Ballard, JO, Goodnight, SH, Hathaway, WE, Hultin, MBVolume:
75
Journal:
Blood
DOI:
10.1182/blood.v75.1.33.33
Date:
January, 1990
File:
PDF, 638 KB
1990
File converter
More search results
More benefits 
